



WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies

BELGIUM

Recent and planned changes in pharmaceutical pricing and reimbursement and overview of the medical devices system

PHARMACEUTICALS			
Changes in pricing		Changes in reimbursement	
01.01.2014:		01.01.2014:	
Reference reimbursement system: increased reduction % (-31% \rightarrow -32,5%) Price reduction for biological medicines: -7,5% 18 years after initial reimbursement of the molecule Ceiling price for sartans and statins Indexation basic fee pharmacist		Annual indexation co-payment ceilings Reference reimbursement system: increased reduction % (-31% → -32,5%)	
$(4,11 \rightarrow 4,16 \text{ euros})$			
 2014: Tax for orphan drugs (orphan drugs were exempted until 2014) May 2014: "cheap drugs": if a 15% price reduction is applied to a biological → considered as a "cheap" pharmaceutical (prescription quota) 01.01.2015: Introduction of a tarification per unit per week for oral-solid pharmaceuticals dispensed by pharmacists (out-patient sector) to patients in residential care (royal decrees published – implementation period foreseen) : new reimbursement level per unit new co-payment per unit new average dispensing fee per week for pharmacists 			
	ME	EDICAL DEVICES	
Pricing and reimbursement system of medical devices			
Competent authorities: marketing authorisation pricing		dicines and health products the Federal Public Service Economy, S.M.E.s, Self-employed and	
reimbursement	National Institute for Health and Disability Insurance		

reimbursement	National Institute for Health and Disability Insurance	
	01.07.2014 (new royal decree in final stage of officialisation): New commission for implants (procedure similar to pharmaceuticals) 	
	 New list of reimbursed medical acts Positive nominative lists of devices for some medical acts 	